Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Safety Bill Produces Restless REMS; Core Of “KEnzi” Is Narrowed But Intact

Executive Summary

The Rx safety oversight system outlined in the legislation passed out of the Senate Health Committee April 18 has a greater focus on active surveillance systems than the bill originally introduced by Sens. Edward Kennedy, D-Mass., and Michael Enzi, R-Wyo

You may also be interested in...



Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization

Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say the system needs reform. Industry and patient advocate groups push for change, while consumer groups press FDA to stand firm.

Battle Lines Clear On Conflict Of Interest Policy In PDUFA Reauthorization

Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say the system needs reform. Industry and patient advocate groups push for change, while consumer groups press FDA to stand firm.

FDA Conflict Of Interest Policy May Be Biggest Conflict Of PDUFA Reauthorization

Commissioner Hamburg says the agency likely does not need legislation to improve its conflict of interest policy, but House members still say system needs reform.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel